Yearly Trends of Overactive Bladder Medication Usage.
Kevin J Chua, Hiren V Patel, Alexandra Tabakin...
https://pubmed.ncbi.nlm.nih.gov/37145398/Actively Recruiting
Led by Walter Reed National Military Medical Center · Updated on 2025-02-19
100
Participants Needed
1
Research Sites
N/A
Total Duration
Overactive bladder OAB and bladder pain syndrome ICBPS are common conditions that impact quality of life, affecting about 17% of people. This research evaluates different antibiotic plans to prevent urinary tract infections UTIs after intradetrusor onabotulinumtoxinA injections, a treatment for OAB and ICBPS. The study aims to find the best timing, duration, and type of antibiotic to reduce UTIs and limit unnecessary antibiotic use that can cause side effects and resistance. Participants will be randomly assigned to one of two groups one group will take a 3-day course of nitrofurantoin twice daily starting at the procedure time, and the other will take a single nitrofurantoin dose at the procedure time. Before the procedure, patients will have urine tests to ensure no current infection. On the day of treatment, patients will receive lidocaine and possibly diazepam for comfort, along with phenazopyridine and nitrofurantoin before the injection. The procedure follows standard medical guidelines. During the study, urine tests will be done if symptoms of UTI appear, and patients will be followed up 30 to 45 days after the procedure via phone, email, or messaging to check for UTIs and other outcomes. The main measure is the rate of UTIs within 30 days after the injection. Additional safety and symptom data will also be collected to evaluate the treatments. Participation will last through this follow-up period to monitor results.
CONDITIONS
Bladder Botox UTI Antibiotic Prophylaxis
J
Jordan Gisseman, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Walter Reed National Military Medical Center
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Single Dose After Procedure | 3-Day Course After Procedure |
|---|---|---|
| What it is | A single oral dose of nitrofurantoin 100 mg prescribed immediately after intradetrusor injection of onabotulinumtoxinA for overactive bladder or bladder pain syndrome. | A 3-day oral course of nitrofurantoin 100 mg given after intradetrusor injection of onabotulinumtoxinA for overactive bladder or bladder pain syndrome. |
| Role in the trial | Test intervention to assess whether a single dose of nitrofurantoin is sufficient for UTI prophylaxis after injection. | Comparator arm evaluating a usual short-course antibiotic regimen for post-procedure UTI prevention. |
| Primary use | Given to reduce the risk of urinary tract infection within 30 days after bladder botox injection. | Prescribed to prevent urinary tract infection following bladder botox procedure. |
| How it is given or performed | Taken orally as one dose after the botox injection procedure. | Taken orally every day for three days starting after the botox injection. |
| Evidence status | Single-dose prophylaxis is being tested and has some published support for comparable UTI prevention rates to multi-day regimens after bladder botox injection, but available trial results remain limited. | 3-day nitrofurantoin courses are commonly used and are guideline-supported for UTI prevention after urologic procedures, but recent evidence shows that longer regimens may not further reduce UTI risk compared to single-dose approaches. |
| Important limitations | Limited published evidence and ongoing research mean the true effectiveness and safety profile of single-dose prophylaxis remain to be fully established in this population. | While longer course prophylaxis is guideline-accepted, repeated use of antibiotics may contribute to resistance or adverse events, and recent studies question whether additional doses improve outcomes. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 days
Participants receive intradetrusor onabotulinumtoxinA injection and take nitrofurantoin antibiotic prophylaxis either as a single dose or a 3-day course starting at the time of the procedure.
1 procedure visit with medication administration
Duration - 30 days
Participants are monitored for urinary tract infections and other adverse effects within 30 days after the procedure.
Visits as needed for symptom assessment and safety monitoring
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kevin J Chua, Hiren V Patel, Alexandra Tabakin...
https://pubmed.ncbi.nlm.nih.gov/37145398/Kalpana Gupta, Thomas M Hooton, Kurt G Naber...
https://pubmed.ncbi.nlm.nih.gov/21292654/Ian Milsom, Karin S Coyne, Sean Nicholson...
https://pubmed.ncbi.nlm.nih.gov/24007713/Justin Houman, Ariel Moradzadeh, Devin N Patel...
https://pubmed.ncbi.nlm.nih.gov/30074062/Govindaraj N Rajkumar, Douglas R Small, Abdul W Mustafa...
https://pubmed.ncbi.nlm.nih.gov/16153215/Joshua S Benner, Michael B Nichol, Eric S Rovner...
https://pubmed.ncbi.nlm.nih.gov/19912188/Michael B Chancellor, Kristen Migliaccio-Walle, Thomas J Bramley...
https://pubmed.ncbi.nlm.nih.gov/24091072/Khaled Maman, Samuel Aballea, Jameel Nazir...
https://pubmed.ncbi.nlm.nih.gov/24275310/Tao Wu, Xi Duan, Chen-Xi Cao...
https://pubmed.ncbi.nlm.nih.gov/25115445/Annarita Mazzariol, Alda Bazaj, Giuseppe Cornaglia
https://pubmed.ncbi.nlm.nih.gov/29271736/Walter Reed National Military Medical Center
Lead Sponsor